Ovarian Cancer Targeted Medication: PARP Inhibitors, Anti-Angiogenic Drugs, Immunotherapy, and More Ovarian cancer is the malignancy with the highest rate of death from tumors of the female ...

Currently, five PARP inhibitor drugs are running in clinical trials for approval. All have shown proof of concept success in germline BRCA mutation carriers. Furthermore, several combinations with ...

While all poly ADP-ribose polymerase (PARP) inhibitors improved progression-free survival, olaparib significantly extended overall survival (OS), making it a preferred option.

Five years AstraZeneca became an oncology trailblazer by getting the first PARP inhibitor class drug Lynparza, approved by the FDA for certain ovarian cancers. Now the UK pharma is aiming to build ...

which would really broaden the use of PARP inhibitors.” The phase 1 PETRA trial of AZD5305 has already begun in solid tumours and O’Connor said the drug will likely be used in cancers with ...

The findings could lead to genetic tests that predict the likelihood of disease recurrence in breast cancer patients and ...

Global Ovarian Cancer Drugs Market size is expected to be worth around USD 9,857 Mn by 2032 from USD 3061 Mn in 2023, growing at a CAGR of 14.3% ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...